NEWS THAT MATTERS
New and updated
Pharmaceutical Benefits Scheme
From 1 August 2022, Australians will have access to new and updated Pharmaceutical Benefits Scheme (PBS) listings, including a new spinal muscular atrophy medicine for adult patients.
2 August 2022
THE PBS listing of nusinersen (Spinraza®) will be extended to include treatment of adult patients diagnosed with spinal muscular atrophy (SMA) whose symptoms appeared before 19 years of age.
SMA is a rare genetic neuromuscular condition which causes progressive muscle wasting (atrophy) and weakness leading to loss of movement.
Until now there have been no treatment options available on the PBS for adults living with SMA.
Approximately one in 35 Australians carry the SMA gene - but most are unaware.
Without a subsidy, families would pay well over $300,000 per year for nusinersen treatment. Now, it costs just $42.50 per script, or $6.80 with a concession card. This will benefit an average of 100 patients per year.
A new long-acting (6-month injection cycle) form of the medicine paliperidone (Invega Hafyera®) will be listed to treat schizophrenia for patients who have been stabilised on 1-monthly or 3-monthly injections.
Schizophrenia is a complex brain disorder affecting between 150,000 and 200,000 Australians, causing an altered experience of reality including delusions and hallucinations.
Without subsidy for paliperidone patients may pay $4,200 per year of treatment. Last year 5,400 people accessed another form of long-acting paliperidone, and they will now have an alternative treatment option.
A new treatment option for those with multiple sclerosis (MS), diroximel fumarate (Vumerity ®) will be made available through the PBS. Without this listing patients could pay up to $8,500 a year on treatment.
MS is a result of damage to myelin – a protective sheath surrounding nerve fibres of the central nervous system. This interferes with messages between the brain and other parts of the body.
“These updates to the PBS will improve the lives for Australians who suffer from SMA, schizophrenia and MS," said Minister for Heath and Aged Care Mark Butler.
“These are remarkable medications that without government support would be unaffordable for thousands of Australians diagnosed with these conditions."
A full list of 1 August changes can be found here.
SUBSCRIBE FOR FREE to the Grapevine News Online and to the monthly e-book edition of the Grapevine Community News. You will receive an email notification every time a news story goes live, keeping you up to date with what is happening in your community.
Our online news update and monthly newspaper is about real local news and events. We will not spam you or share your details with third parties.